Smartphone App Study for Organ Transplant Patients
Protocol: STUDY00005849
Full Title
Technology Enabled And Molecular Monitoring of the Allograft and Transplant rEcipient
This study is for patients who have received a single solid organ transplant of either the lung, liver, kidney, or heart. The purpose of this study is to evaluate the impact of the AlloCare app on the early post-transplant period.

The AlloCare app is a free smart phone-based application that allows transplant patients to track their health activities and communicate with their care team and community. The app provides medication management including up-to-date medication lists, medication reminders, and adherence tracking. Participants can use the app to record and monitor other wellness activities such as water intake, steps, mood, and sleep, as well as scheduling blood-draws and receiving lab visit reminders. Finally, the app provides educational materials and a virtual connection to a community of other post-transplant patients.

This study will last for 1 year and participants will be randomly assigned (similar to flip of a coin) to either a standard care group or an AlloCare group. This study will not provide any medical care. Medical care, including diagnostic testing, will be directed and provided by each participant’s doctor and clinic.
Compensation: No
Participants with a single solid organ transplant of either the lung, liver, kidney or heart.
Age Group: Adults
Principal Investigator: LIISE KAYLER Open Study
+1 716-645-1172
Want to Learn More?

Let us know how the study team can reach you. If you do not hear back within 2 business days, reach out to the study team directly at the contact information above or email and someone will assist you.

Your information will be shared only with the research study team for recruitment purposes and designated CTSI personnel for project quality assurance and will remain confidential. Your information will be stored indefinitely. Should you no longer want this information to be provided in the aforementioned ways, please contact